{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:19:07Z","timestamp":1788232747427,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13046-018-0843-y","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T14:41:27Z","timestamp":1532529687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22\/IPO7\/HIF-1\u03b1 axis"],"prefix":"10.1186","volume":"37","author":[{"given":"Francesca","family":"Monteleone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"843_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"843_CR2","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood. 2010;116:3758\u201365.","journal-title":"Blood"},{"key":"843_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58\u201360.","journal-title":"Blood"},{"key":"843_CR4","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","volume":"123","author":"KP Ng","year":"2014","unstructured":"Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CT, Poellinger L, Ong ST. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood. 2014;123:3316\u201326.","journal-title":"Blood"},{"key":"843_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12013-014-0434-2","volume":"72","author":"H Chen","year":"2015","unstructured":"Chen H, Shen Y, Gong F, Jiang Y, Zhang R. HIF-alpha promotes chronic myelogenous leukemia cell proliferation by upregulating p21 expression. Cell Biochem Biophys. 2015;72:179\u201383.","journal-title":"Cell Biochem Biophys"},{"key":"843_CR6","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","volume":"119","author":"H Zhang","year":"2012","unstructured":"Zhang H, Li H, Xi HS, Li S. HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012;119:2595\u2013607.","journal-title":"Blood"},{"key":"843_CR7","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1038\/onc.2010.67","volume":"29","author":"F Zhao","year":"2010","unstructured":"Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene. 2010;29:2962\u201372.","journal-title":"Oncogene"},{"key":"843_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semcancer.2017.06.011","volume":"46","author":"C Braicu","year":"2017","unstructured":"Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, Berindan-Neagoe I. Nutrigenomics in cancer: revisiting the effects of natural compounds. Semin Cancer Biol. 2017;46:84\u2013106.","journal-title":"Semin Cancer Biol"},{"key":"843_CR9","first-page":"645","volume":"35","author":"NG Vallianou","year":"2015","unstructured":"Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015;35:645\u201351.","journal-title":"Anticancer Res"},{"key":"843_CR10","doi-asserted-by":"crossref","first-page":"30420","DOI":"10.18632\/oncotarget.8483","volume":"7","author":"S Taverna","year":"2016","unstructured":"Taverna S, Fontana S, Monteleone F, Pucci M, Saieva L, De Caro V, Cardinale VG, Giallombardo M, Vicario E, Rolfo C, et al. Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype via exosomal miR-21. Oncotarget. 2016;7:30420\u201339.","journal-title":"Oncotarget"},{"key":"843_CR11","doi-asserted-by":"publisher","first-page":"21918","DOI":"10.18632\/oncotarget.4204","volume":"6","author":"S Taverna","year":"2015","unstructured":"Taverna S, Giallombardo M, Pucci M, Flugy A, Manno M, Raccosta S, Rolfo C, De Leo G, Alessandro R. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget. 2015;6:21918\u201333.","journal-title":"Oncotarget"},{"issue":"016717","key":"843_CR12","first-page":"11","volume":"O111","author":"LC Gillet","year":"2012","unstructured":"Gillet LC, Navarro P, Tate S, Rost H, Selevsek N, Reiter L, Bonner R, Aebersold R. Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;O111(016717):11.","journal-title":"Mol Cell Proteomics"},{"key":"843_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17321-1","volume":"7","author":"H Li","year":"2017","unstructured":"Li H, Wang Y, Fu Q, Li X, Wu C, Shen Z, Zhang Q, Qin P, Shen J, Xia X. Integrated genomic and proteomic analyses of high-level chloramphenicol resistance in campylobacter jejuni. Sci Rep. 2017;7:16973.","journal-title":"Sci Rep"},{"key":"843_CR14","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkw936","volume":"45","author":"EW Deutsch","year":"2017","unstructured":"Deutsch EW, Csordas A, Sun Z, Jarnuczak A, Perez-Riverol Y, Ternent T, Campbell DS, Bernal-Llinares M, Okuda S, Kawano S, et al. The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition. Nucleic Acids Res. 2017;45:D1100\u20136.","journal-title":"Nucleic Acids Res"},{"key":"843_CR15","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","volume":"44","author":"JA Vizcaino","year":"2016","unstructured":"Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44:D447\u201356.","journal-title":"Nucleic Acids Res"},{"key":"843_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep45913","volume":"7","author":"Y Gao","year":"2017","unstructured":"Gao Y, Wang X, Sang Z, Li Z, Liu F, Mao J, Yan D, Zhao Y, Wang H, Li P, et al. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues. Sci Rep. 2017;7:45913.","journal-title":"Sci Rep"},{"key":"843_CR17","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/pmic.201400515","volume":"15","author":"M Pathan","year":"2015","unstructured":"Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597\u2013601.","journal-title":"Proteomics"},{"key":"843_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091\u20133.","journal-title":"Bioinformatics"},{"key":"843_CR19","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"843_CR20","doi-asserted-by":"publisher","first-page":"19514","DOI":"10.18632\/oncotarget.4004","volume":"6","author":"S Raimondo","year":"2015","unstructured":"Raimondo S, Naselli F, Fontana S, Monteleone F, Lo Dico A, Saieva L, Zito G, Flugy A, Manno M, Di Bella MA, et al. Citrus Limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death. Oncotarget. 2015;6:19514\u201327.","journal-title":"Oncotarget"},{"key":"843_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2010.10.007","volume":"300","author":"C Corrado","year":"2011","unstructured":"Corrado C, Raimondo S, Flugy AM, Fontana S, Santoro A, Stassi G, Marfia A, Iovino F, Arlinghaus R, Kohn EC, et al. Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. Cancer Lett. 2011;300:205\u201314.","journal-title":"Cancer Lett"},{"key":"843_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"843_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"key":"843_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/iub.1484","volume":"68","author":"T Stelma","year":"2016","unstructured":"Stelma T, Chi A, van der Watt PJ, Verrico A, Lavia P, Leaner VD. Targeting nuclear transporters in cancer: diagnostic, prognostic and therapeutic potential. IUBMB Life. 2016;68:268\u201380.","journal-title":"IUBMB Life"},{"key":"843_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbrc.2009.09.093","volume":"390","author":"G Chachami","year":"2009","unstructured":"Chachami G, Paraskeva E, Mingot JM, Braliou GG, Gorlich D, Simos G. Transport of hypoxia-inducible factor HIF-1alpha into the nucleus involves importins 4 and 7. Biochem Biophys Res Commun. 2009;390:235\u201340.","journal-title":"Biochem Biophys Res Commun"},{"key":"843_CR26","doi-asserted-by":"crossref","unstructured":"Zhou S, Zhang S, Shen H, Chen W, Xu H, Chen X, Sun D, Zhong S, Zhao J, Tang J: Curcumin inhibits cancer progression through regulating expression of microRNAs. Tumour Biol 2017, 39:1010428317691680.","DOI":"10.1177\/1010428317691680"},{"key":"843_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","volume":"120","author":"BP Lewis","year":"2005","unstructured":"Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15\u201320.","journal-title":"Cell"},{"key":"843_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.molcel.2007.06.017","volume":"27","author":"A Grimson","year":"2007","unstructured":"Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91\u2013105.","journal-title":"Mol Cell"},{"key":"843_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ijc.27731","volume":"132","author":"J Szczyrba","year":"2013","unstructured":"Szczyrba J, Nolte E, Hart M, Doll C, Wach S, Taubert H, Keck B, Kremmer E, Stohr R, Hartmann A, et al. Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int J Cancer. 2013;132:775\u201384.","journal-title":"Int J Cancer"},{"key":"843_CR30","doi-asserted-by":"publisher","first-page":"20555","DOI":"10.18632\/oncotarget.4111","volume":"6","author":"NA Sibbesen","year":"2015","unstructured":"Sibbesen NA, Kopp KL, Litvinov IV, Jonson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-cell lymphoma. Oncotarget. 2015;6:20555\u201369.","journal-title":"Oncotarget"},{"key":"843_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3109\/02713683.2011.647224","volume":"37","author":"S Sreenivasan","year":"2012","unstructured":"Sreenivasan S, Thirumalai K, Danda R, Krishnakumar S. Effect of curcumin on miRNA expression in human Y79 retinoblastoma cells. Curr Eye Res. 2012;37:421\u20138.","journal-title":"Curr Eye Res"},{"key":"843_CR32","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/mnfr.201300201","volume":"57","author":"MH Teiten","year":"2013","unstructured":"Teiten MH, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. Mol Nutr Food Res. 2013;57:1619\u201329.","journal-title":"Mol Nutr Food Res"},{"key":"843_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1158\/1535-7163.MCT-07-2272","volume":"7","author":"M Sun","year":"2008","unstructured":"Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7:464\u201373.","journal-title":"Mol Cancer Ther"},{"key":"843_CR34","first-page":"3004","volume":"2233","author":"H Mirzaei","year":"2017","unstructured":"Mirzaei H, Masoudifar A, Sahebkar A, Zare N, Nahand JS, Rashidi B, Mehrabian E, Mohammadi M, Mirzaei HR, Jaafari MR. MicroRNA: a novel target of curcumin in Cancer therapy. J Cell Physiol. 2017;2233:3004\u201315.","journal-title":"J Cell Physiol."},{"key":"843_CR35","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.3892\/ol.2017.6053","volume":"13","author":"X Wang","year":"2017","unstructured":"Wang X, Hang Y, Liu J, Hou Y, Wang N, Wang M. Anticancer effect of curcumin inhibits cell growth through miR-21\/PTEN\/Akt pathway in breast cancer cell. Oncol Lett. 2017;13:4825\u201331.","journal-title":"Oncol Lett"},{"key":"843_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000114","volume":"2","author":"BT Kurien","year":"2015","unstructured":"Kurien BT, Harris VM, Quadri SM, Coutinho-de Souza P, Cavett J, Moyer A, Ittiq B, Metcalf A, Ramji HF, Truong D, et al. Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr\/lpr mice treated with ultrasoluble curcumin\/turmeric: increased survival with curcumin treatment. Lupus Sci Med. 2015;2:e000114.","journal-title":"Lupus Sci Med"},{"key":"843_CR37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2174\/1567201811666140825130003","volume":"11","author":"U Hani","year":"2014","unstructured":"Hani U, Shivakumar HG. Solubility enhancement and delivery systems of curcumin a herbal medicine: a review. Curr Drug Deliv. 2014;11:792\u2013804.","journal-title":"Curr Drug Deliv"},{"key":"843_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/1061186X.2016.1157883","volume":"24","author":"W Liu","year":"2016","unstructured":"Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, Zhai G. Oral bioavailability of curcumin: problems and advancements. J Drug Target. 2016;24:694\u2013702.","journal-title":"J Drug Target"},{"key":"843_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/adt.2007.064","volume":"5","author":"BT Kurien","year":"2007","unstructured":"Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol. 2007;5:567\u201376.","journal-title":"Assay Drug Dev Technol"},{"key":"843_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2015.05.003","volume":"65","author":"Y Guo","year":"2015","unstructured":"Guo Y, Li Y, Shan Q, He G, Lin J, Gong Y. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT\/mTOR pathway and BCR\/ABL gene expression in Ph+ acute lymphoblastic leukemia. Int J Biochem Cell Biol. 2015;65:1\u201311.","journal-title":"Int J Biochem Cell Biol"},{"key":"843_CR41","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1021\/pr0704128","volume":"6","author":"S Fontana","year":"2007","unstructured":"Fontana S, Alessandro R, Barranca M, Giordano M, Corrado C, Zanella-Cleon I, Becchi M, Kohn EC, De Leo G. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J Proteome Res. 2007;6:4330\u201342.","journal-title":"J Proteome Res"},{"key":"843_CR42","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1158\/0008-5472.CAN-07-6246","volume":"68","author":"V Milacic","year":"2008","unstructured":"Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008;68:7283\u201392.","journal-title":"Cancer Res"},{"key":"843_CR43","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2174\/187152012802649978","volume":"12","author":"M Shen","year":"2012","unstructured":"Shen M, Chan TH, Dou QP. Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization. Anti Cancer Agents Med Chem. 2012;12:891\u2013901.","journal-title":"Anti Cancer Agents Med Chem"},{"key":"843_CR44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891\u20139.","journal-title":"Nat Rev Cancer"},{"key":"843_CR45","first-page":"36","volume":"7","author":"S Ganapathy-Kanniappan","year":"2017","unstructured":"Ganapathy-Kanniappan S. Taming tumor glycolysis and potential implications for immunotherapy. Front Oncol. 2017;7:36.","journal-title":"Front Oncol"},{"key":"843_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297\u2013308.","journal-title":"Cancer Cell"},{"key":"843_CR47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrc2468","volume":"8","author":"NC Denko","year":"2008","unstructured":"Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705\u201313.","journal-title":"Nat Rev Cancer"},{"key":"843_CR48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1593\/neo.07724","volume":"10","author":"IF Robey","year":"2008","unstructured":"Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 2008;10:745\u201356.","journal-title":"Neoplasia"},{"key":"843_CR49","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1476-5381.2009.00345.x","volume":"158","author":"J Klawitter","year":"2009","unstructured":"Klawitter J, Kominsky DJ, Brown JL, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol. 2009;158:588\u2013600.","journal-title":"Br J Pharmacol"},{"key":"843_CR50","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1124\/mol.106.025817","volume":"70","author":"H Choi","year":"2006","unstructured":"Choi H, Chun YS, Kim SW, Kim MS, Park JW. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol. 2006;70:1664\u201371.","journal-title":"Mol Pharmacol"},{"key":"843_CR51","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1530\/JOE-12-0207","volume":"214","author":"B Shan","year":"2012","unstructured":"Shan B, Schaaf C, Schmidt A, Lucia K, Buchfelder M, Losa M, Kuhlen D, Kreutzer J, Perone MJ, Arzt E, et al. Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. J Endocrinol. 2012;214:389\u201398.","journal-title":"J Endocrinol"},{"key":"843_CR52","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/tra.12090","volume":"14","author":"M Niu","year":"2013","unstructured":"Niu M, Wu S, Mao L, Yang Y. CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic. 2013;14:1042\u201352.","journal-title":"Traffic"},{"key":"843_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.semcancer.2014.03.001","volume":"27","author":"JG Turner","year":"2014","unstructured":"Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014;27:62\u201373.","journal-title":"Semin Cancer Biol"},{"key":"843_CR54","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/jca.7080","volume":"4","author":"JG Turner","year":"2013","unstructured":"Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer. 2013;4:614\u201325.","journal-title":"J Cancer"},{"key":"843_CR55","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/1535-7163.MCT-15-0104","volume":"14","author":"S Kazim","year":"2015","unstructured":"Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A. Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic Cancer. Mol Cancer Ther. 2015;14:1570\u201381.","journal-title":"Mol Cancer Ther"},{"key":"843_CR56","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/01635581.2010.509835","volume":"62","author":"A Goel","year":"2010","unstructured":"Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62:919\u201330.","journal-title":"Nutr Cancer"},{"key":"843_CR57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-0-387-46401-5_12","volume":"595","author":"P Limtrakul","year":"2007","unstructured":"Limtrakul P. Curcumin as chemosensitizer. Adv Exp Med Biol. 2007;595:269\u2013300.","journal-title":"Adv Exp Med Biol"},{"key":"843_CR58","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/bcp.13327","volume":"83","author":"NAG Lankheet","year":"2017","unstructured":"Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017;83:2195\u2013204.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0843-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-018-0843-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0843-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T17:56:38Z","timestamp":1604685398000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0843-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0843-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"assertion":[{"value":"29 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"170"}}